Tonio Pera

Dr. Tonio Pera


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
TPTonio Pera
Tonio Pera
RPRaymond Penn
Raymond Penn

1 November 2022 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
ETEric Tompkins
Eric Tompkins
BMBogdana Mimic
Bogdana Mimic
KCKarina Cuevas-Mora
Karina Cuevas-Mora
HSHannah Schorsch
Hannah Schorsch
SSSushrut D. Shah
Sushrut D. Shah
TPTonio Pera
Tonio Pera
G protein–coupled receptors (GPCRs) not only are turned on or off to control canonical G protein signaling but also may be fine-tuned to promote qualitative/biased signaling. Qualitative signaling by M3 muscarinic acetylcholine receptors (mAChRs) has been proposed, but its impact on physiologic systems remains unclear, and currently no biased M3 mAChR ligands have been described. Herein, we identify PD 102807 as a biased M3 ligand and delineate its signaling and function in human airway smooth muscle (ASM) cells. PD 102807 induced M3-mediated β-arrestin recruitment but not calcium mobilization. PD 102807 inhibited methacholine (MCh)-induced calcium mobilization in (M3-expressing) ASM cells. PD 102807 induced phosphorylation of AMP-activated protein kinase (AMPK) and the downstream effector acetyl–coenzyme A carboxylase (ACC). PD 102807– induced phosphorylated (p)-AMPK levels were greatly reduced in ASM cells with minimal M3 expression and were not inhibited by the Gq inhibitor YM-254890. Induction of p-AMPK and p-ACC was inhibited by β-arrestin 1 or GRK2/3 knockdown. Similarly, MCh induced phosphorylation of AMPK/ACC, but these effects were Gq dependent and unaffected by GRK2/3 knockdown. Consistent with the known ability of AMPK to inhibit transforming growth factor β (TGF-β)–mediated functions, PD 102807 inhibited TGF-β–induced SMAD-Luc activity, sm-α-actin expression, actin stress fiber formation, and ASM cell hypercontractility. These findings reveal that PD 102807 is a biased M3 ligand that inhibits M3-transduced Gq signaling but promotes Gq protein-independent, GRK-/arrestin-dependent, M3-mediated AMPK signaling, which in turn regulates ASM phenotype and contractile function. Consequently, biased M3 ligands hold significant promise as therapeutic agents capable of exploiting the pleiotropic nature of M3 signaling.

1 May 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TPTonio Pera
Tonio Pera
ETEric Tompkins
Eric Tompkins
MKMichael Katz
Michael Katz
BWBin Wang
Bin Wang
DDDeepak A. Deshpande
Deepak A. Deshpande
RPRaymond Penn
Raymond Penn
Na + /H + exchanger regulatory factor 1 (NHERF1; also known as ezrin‐radixin‐moesin–binding phosphoprotein 50) is a PSD‐95, disc large, zona occludens‐1 adapter that acts as a scaffold for signaling complexes and cytoskeletal‐plasma membrane interactions. NHERF1 is crucial to β‐2‐adrenoceptor (β 2 AR)‐mediated activation of cystic fibrosis transmembrane conductance regulator (CFTR) in epithelial cells, and NHERF1 has been proposed to mediate the recycling of internalized β 2 AR back to the cell membrane. In the current study, we assessed the role of NHERF1 in regulating cAMP‐mediated signaling and immunomodulatory functions in airway smooth muscle (ASM). NHERF1 knockdown attenuated the induction of (protein kinase A) phospho–vasodilator‐stimulated phosphoprotein (p‐VASP) by isoproterenol (ISO), prostaglandin E 2 (PGE 2 ), or forskolin (FSK) as well as the induction of p‐heat shock protein 20 after 4 h of stimulation with ISO and FSK. NHERF1 knockdown fully abrogated the ISO‐, PGE 2 ‐, and FSK‐induced IL‐6 gene expression and cytokine production without affecting cAMP‐mediated phosphodiesterase 4D (PDE4D) gene expression, phospho–cAMP response element–binding protein (p‐CREB), and cAMP response element (CRE)‐Luc, or PDGF‐induced cyclin D1 expression. Interestingly, NHERF1 knockdown prevented ISO‐induced chromatin‐binding of the transcription factor CCAAT‐enhancer–binding protein‐β (c/EBPβ). c/EBPβ knockdown almost completely abrogated the cAMP‐mediated IL‐6 but not PDE4D gene expression. The differential regulation of cAMP‐induced signaling and gene expression in our study indicates a role for NHERF1 in the compartmentalization of cAMP signaling in ASM.—Pera, T., Tompkins, E., Katz, M., Wang, B., Deshpande, D. A., Weinman, E. J., Penn, R. B. Specificity of NHERF1 regulation of GPCR signaling and function in human airway smooth muscle. FASEB J. 33, 9008–9016 (2019). www.fasebj.org

1 September 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ETEric Tompkins
Eric Tompkins
BMBogdana Mimic
Bogdana Mimic
RPRaymond Penn
Raymond Penn
TPTonio Pera
Tonio Pera
Airway smooth muscle (ASM) cells attain a hypercontractile phenotype during obstructive airway diseases. We recently identified a biased M3 muscarinic acetylcholine receptor (mAChR) ligand, PD 102807, that induces GRK-/arrestin-dependent AMP-activated protein kinase (AMPK) activation to inhibit transforming growth factor-β-induced hypercontractile ASM phenotype. Conversely, the balanced mAChR agonist, methacholine (MCh), activates AMPK yet does not regulate ASM phenotype. In the current study, we demonstrate that PD 102807- and MCh-induced AMPK activation both depend on Ca2+/calmodulin-dependent kinase kinases (CaMKKs). However, MCh-induced AMPK activation is calcium-dependent and mediated by CaMKK1 and CaMKK2 isoforms. In contrast, PD 102807-induced signaling is calcium-independent and mediated by the atypical subtype protein kinase C-iota and the CaMKK1 (but not CaMKK2) isoform. Both MCh- and PD 102807-induced AMPK activation involve the AMPK α1 isoform. PD 102807-induced AMPK α1 (but not AMPK α2) isoform activation mediates inhibition of the mammalian target of rapamycin complex 1 (mTORC1) in ASM cells, as demonstrated by increased Raptor (regulatory-associated protein of mTOR) phosphorylation as well as inhibition of phospho-S6 protein and serum response element-luciferase activity. The mTORC1 inhibitor rapamycin and the AMPK activator metformin both mimic the ability of PD 102807 to attenuate transforming growth factor-β-induced α-smooth muscle actin expression (a marker of hypercontractile ASM). These data indicate that PD 102807 transduces a signaling pathway (AMPK-mediated mTORC1 inhibition) qualitatively distinct from canonical M3 mAChR signaling to prevent pathogenic remodeling of ASM, thus demonstrating PD 102807 is a biased M3 mAChR ligand with therapeutic potential for the management of obstructive airway disease.